Louvain Drug Research Institute

The general objective of the Louvain Drug Research Institute (LDRI) is to develop cutting-edge research, fundamental and/or applied research, in the field of drugs. Overall research activities are developed from target identification & validation to clinical practice through hit identification/hit to lead, preclinical evaluation, pharmaceutics, clinical assays and optimization of clinical practice.


 Bridging sciences for better health is the LDRI’s motto. The LDRI is proud of the diversity and wealth of its research despite its relatively small size, and the limited number of senior researchers who are also involved in teaching and institutional activities. The members of the LDRI join their forces to form a multidisciplinary Institute where all major aspects of the drug are covered. The research activities range from the design or identification of a new drug (and the discovery of new targets) to its optimal use through all modern means of evaluation. The approaches use in vitro (membranes and cells) and in vivo pre-clinical models (small animals). Patients-oriented research is focused on the pharmacokinetics/pharmacogenomics and clinical pharmacy.



President : Nathalie Delzenne
Vice-Presidents : Raphaël Frédérick, Giulio Muccioli, Françoise Van Bambeke

Secretariat : Stéphanie Lozes - 32 2 764 73 28

latest news Fil RSS
Researchers at the LDRI (UCL) and at the VIB (KU Leuven reveal an innovative strategy to fight against bacterial biofilms. Professor Françoise Van Bambeke’s teams from the Louvain Drug Research Institute of UCL and Professor Patrick Van Dijck’s teams from VIB and KU Leuven are opening up a new path in treating serious infections which affect patients in hospital. The results of the study are published in the scientific journal, Nature Communications.
[> more]
On September 1, 2016, three young researchers, Séverine Henrard, Laure Bindels and Julian Leprince, joined the Louvain Drug Research Institute as PI to pursue their research.
[> more]
30 % des admissions sont liées à la prise d’un mauvais médicament
[> more]
[> more]
| 22/09/2016 |
Monday, 05 December - Salle Couvreur - 13h00

Mechanism of aggregation of polyglutamine proteins that are associated with neurodegenerative amyloidoses

[ > more]
Role of membrane cholesterol in ginsenoside Rh2-induced apoptosis in human leukemic U937 ce

Tuesday 08 November - 16h - Salle Couvreur (73/0)

[> more]
Anti-parasitic activities of essential oils extracted from Vietnamese plants

Monday 12 December - 13h - Salle Couvreur (73/0)

[> more]